Oncology Sub-team

Skip to main content

Addressing innovative design questions specific to oncology drug development, including biomarker-driven and adaptive designs.

Overview

The Oncology Sub-team is co-chaired by Philip He (Daiichi Sankyo) and Laura Fernandes (COTA). The sub-team focuses on design innovations specific to oncology, including biomarker-driven patient selection, response-adaptive randomization, smooth
Phase 2/3 designs, and the growing role of real-world evidence in oncology development programs.

Get Involved

Contact Philip He or Laura Fernandes by contacting the IDSWG Leadership Team.

All Sub-teams

Page last reviewed: